Fust Matthew K
Insider CIK 1397266 · ONXX EVP & Chief Financial Officer · MGNX Director · RARE Director · DERM Director · ATRA Director · CRNX Director · NMRA Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals, | D To issuer deriv | 2026-09-01 | 2026-09-01 | 10,350 | $52.67 | $545.1K | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | D To issuer deriv | 2026-09-01 | 2026-09-01 | 12,500 | $40.29 | $503.6K | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | D To issuer deriv | 2026-09-01 | 2026-09-01 | 17,500 | $64.68 | $1.13M | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | D To issuer deriv | 2026-09-01 | 2026-09-01 | 2,092 | $83.09 | $173.8K | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | D To issuer deriv | 2026-09-01 | 2026-09-01 | 9,730 | $49.13 | $478.0K | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | D To issuer | 2026-09-01 | 2026-09-01 | 5,925 | $85.00 | $503.6K | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | D To issuer | 2026-09-01 | 2026-09-01 | 22,836 | $85.00 | $1.94M | 5,925 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | D To issuer deriv | 2026-09-01 | 2026-09-01 | 9,730 | $49.13 | $478.0K | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | D To issuer deriv | 2026-09-01 | 2026-09-01 | 10,350 | $52.67 | $545.1K | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | D To issuer deriv | 2026-09-01 | 2026-09-01 | 12,500 | $40.29 | $503.6K | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | D To issuer deriv | 2026-09-01 | 2026-09-01 | 17,500 | $64.68 | $1.13M | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | D To issuer deriv | 2026-09-01 | 2026-09-01 | 2,092 | $83.09 | $173.8K | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | D To issuer | 2026-09-01 | 2026-09-01 | 5,925 | $85.00 | $503.6K | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | D To issuer | 2026-09-01 | 2026-09-01 | 22,836 | $85.00 | $1.94M | 5,925 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | A Award deriv | 2026-06-18 | 2026-06-22 | 9,730 | — | $0 | 9,730 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | A Award | 2026-06-18 | 2026-06-22 | 5,925 | — | $0 | 28,761 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award | 2026-06-09 | 2026-06-11 | 12,000 | — | $0 | 30,188 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2026-05-27 | 2026-05-29 | 80,000 | — | $0 | 80,000 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award deriv | 2026-05-14 | 2026-05-18 | 14,058 | — | $0 | 14,058 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award | 2026-05-14 | 2026-05-18 | 7,751 | — | $0 | 33,696 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise deriv | 2025-09-26 | 2025-09-30 | 10,000 | — | $0 | 2,092 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise | 2025-09-26 | 2025-09-30 | 10,000 | $1.91 | $19.1K | 38,836 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | S Sale | 2025-09-26 | 2025-09-30 | 16,000 | $44.75 | $716.0K | 22,836 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | A Award deriv | 2025-06-11 | 2025-06-13 | 10,350 | — | $0 | 10,350 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | A Award | 2025-06-11 | 2025-06-13 | 6,900 | — | $0 | 28,836 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award | 2025-06-10 | 2025-06-12 | 7,828 | — | $0 | 18,188 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-05-28 | 2025-05-30 | 85,586 | — | $0 | 85,586 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | D To issuer deriv | 2025-05-28 | 2025-05-30 | 28,571 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-05-28 | 2025-05-30 | 80,000 | — | $0 | 80,000 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-05-28 | 2025-05-30 | 28,571 | — | $0 | 28,571 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | D To issuer deriv | 2025-05-28 | 2025-05-30 | 27,802 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | D To issuer deriv | 2025-05-28 | 2025-05-30 | 85,586 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-05-28 | 2025-05-30 | 27,802 | — | $0 | 27,802 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award deriv | 2025-05-15 | 2025-05-19 | 10,787 | — | $0 | 10,787 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award | 2025-05-15 | 2025-05-19 | 5,740 | — | $0 | 25,945 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-02-13 | 2025-02-18 | 27,802 | — | $0 | 27,802 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-02-13 | 2025-02-18 | 85,586 | — | $0 | 85,586 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | D To issuer deriv | 2025-02-13 | 2025-02-18 | 28,571 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | D To issuer deriv | 2025-02-13 | 2025-02-18 | 27,802 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | D To issuer deriv | 2025-02-13 | 2025-02-18 | 85,586 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-02-13 | 2025-02-18 | 28,571 | — | $0 | 28,571 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | M Exercise deriv | 2024-10-18 | 2024-10-18 | 6,205 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | M Exercise deriv | 2024-10-18 | 2024-10-18 | 7,844 | — | $0 | 85,586 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | S Sale | 2024-10-18 | 2024-10-18 | 14,049 | $17.03 | $239.3K | 20,100 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | M Exercise | 2024-10-18 | 2024-10-18 | 7,844 | $2.52 | $19.8K | 34,149 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | M Exercise | 2024-10-18 | 2024-10-18 | 6,205 | $8.79 | $54.5K | 26,305 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | M Exercise deriv | 2024-10-17 | 2024-10-18 | 1,800 | — | $0 | 6,205 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | M Exercise deriv | 2024-10-17 | 2024-10-18 | 3,783 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | M Exercise deriv | 2024-10-17 | 2024-10-18 | 2,156 | — | $0 | 93,430 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | S Sale | 2024-10-17 | 2024-10-18 | 7,739 | $17.01 | $131.6K | 20,100 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | M Exercise | 2024-10-17 | 2024-10-18 | 2,156 | $2.52 | $5.4K | 27,839 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | M Exercise | 2024-10-17 | 2024-10-18 | 1,800 | $8.79 | $15.8K | 25,683 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | M Exercise | 2024-10-17 | 2024-10-18 | 3,783 | $8.32 | $31.5K | 23,883 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award deriv | 2024-06-18 | 2024-06-20 | 9,900 | — | $0 | 9,900 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award | 2024-06-18 | 2024-06-20 | 5,345 | — | $0 | 20,205 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2024-06-13 | 2024-06-14 | 28,571 | — | $0 | 28,571 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award | 2024-06-13 | 2024-06-14 | 20,100 | — | $0 | 20,100 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | A Award deriv | 2024-06-07 | 2024-06-11 | 12,500 | — | $0 | 12,500 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | A Award | 2024-06-07 | 2024-06-11 | 3,400 | — | $0 | 21,936 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award | 2024-03-31 | 2024-04-02 | 150,000 | — | $0 | 259,000 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise deriv | 2024-03-20 | 2024-03-22 | 17,500 | — | $0 | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise deriv | 2024-03-20 | 2024-03-22 | 12,500 | — | $0 | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise deriv | 2024-03-20 | 2024-03-22 | 12,500 | — | $0 | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise deriv | 2024-03-20 | 2024-03-22 | 17,500 | — | $0 | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise | 2024-03-20 | 2024-03-22 | 12,500 | $23.24 | $290.5K | 31,036 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | S Sale | 2024-03-20 | 2024-03-22 | 12,500 | $43.57 | $544.6K | 18,536 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise | 2024-03-20 | 2024-03-22 | 12,500 | $23.23 | $290.4K | 31,036 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | S Sale | 2024-03-20 | 2024-03-22 | 17,500 | $43.58 | $762.6K | 18,536 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise | 2024-03-20 | 2024-03-22 | 17,500 | $20.23 | $354.0K | 36,036 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise | 2024-03-20 | 2024-03-22 | 17,500 | $18.29 | $320.1K | 36,036 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | S Sale | 2024-03-20 | 2024-03-22 | 12,500 | $43.57 | $544.6K | 18,536 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | S Sale | 2024-03-20 | 2024-03-22 | 17,500 | $45.50 | $796.3K | 18,536 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | S Sale | 2024-03-07 | 2024-03-11 | 7,500 | $50.88 | $381.6K | 14,860 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | S Sale | 2024-03-07 | 2024-03-11 | 2,145 | $50.85 | $109.1K | 22,360 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | S Sale | 2024-03-07 | 2024-03-11 | 2,550 | $50.89 | $129.8K | 24,505 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2023-09-14 | 2023-09-18 | 27,802 | — | $0 | 27,802 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | A Award deriv | 2023-06-16 | 2023-06-21 | 17,500 | — | $0 | 17,500 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | A Award | 2023-06-16 | 2023-06-21 | 6,000 | — | $0 | 18,536 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award deriv | 2023-06-07 | 2023-06-09 | 7,110 | — | $0 | 7,110 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award | 2023-06-07 | 2023-06-09 | 3,860 | — | $0 | 30,355 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | D To issuer | 2023-06-07 | 2023-06-09 | 3,300 | $51.82 | $171.0K | 27,055 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award deriv | 2023-05-31 | 2023-06-02 | 79,500 | — | $0 | 79,500 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award | 2023-05-31 | 2023-06-02 | 57,000 | — | $0 | 109,000 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise deriv | 2022-07-13 | 2022-07-15 | 5,700 | — | $0 | 0 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | S Sale | 2022-07-13 | 2022-07-15 | 5,700 | $20.96 | $119.5K | 12,536 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise | 2022-07-13 | 2022-07-15 | 5,700 | $1.45 | $8.3K | 18,236 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award deriv | 2022-06-24 | 2022-06-28 | 6,245 | — | $0 | 6,245 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award | 2022-06-24 | 2022-06-28 | 3,300 | — | $0 | 26,495 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award deriv | 2022-06-23 | 2022-06-27 | 31,500 | — | $0 | 31,500 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award | 2022-06-23 | 2022-06-27 | 20,500 | — | $0 | 52,000 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | A Award deriv | 2022-06-17 | 2022-06-21 | 17,500 | — | $0 | 17,500 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | M Exercise deriv | 2022-03-04 | 2022-03-08 | 7,500 | — | $0 | 0 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | M Exercise | 2022-03-04 | 2022-03-08 | 7,500 | $40.37 | $302.8K | 23,195 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | S Sale | 2021-11-04 | 2021-11-05 | 13,354 | $19.50 | $260.4K | 31,500 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise deriv | 2021-11-01 | 2021-11-03 | 8,954 | — | $0 | 12,092 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | S Sale | 2021-11-01 | 2021-11-03 | 8,954 | $25.50 | $228.3K | 12,536 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise | 2021-11-01 | 2021-11-03 | 8,954 | $1.91 | $17.1K | 21,490 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise deriv | 2021-09-08 | 2021-09-09 | 6,046 | — | $0 | 21,046 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise | 2021-09-08 | 2021-09-09 | 6,046 | $1.91 | $11.5K | 18,582 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | S Sale | 2021-09-08 | 2021-09-09 | 6,046 | $25.50 | $154.2K | 12,536 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise deriv | 2021-07-26 | 2021-07-27 | 5,000 | — | $0 | 27,092 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | S Sale | 2021-07-26 | 2021-07-27 | 5,000 | $19.59 | $98.0K | 12,536 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise | 2021-07-26 | 2021-07-27 | 5,000 | $1.91 | $9.6K | 17,536 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise deriv | 2021-07-19 | 2021-07-20 | 5,000 | — | $0 | 32,092 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise | 2021-07-19 | 2021-07-20 | 5,000 | $1.91 | $9.6K | 17,536 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | S Sale | 2021-07-19 | 2021-07-20 | 5,000 | $19.50 | $97.5K | 12,536 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise deriv | 2021-07-12 | 2021-07-13 | 5,000 | — | $0 | 37,092 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | S Sale | 2021-07-12 | 2021-07-13 | 5,000 | $20.71 | $103.5K | 12,536 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise | 2021-07-12 | 2021-07-13 | 5,000 | $1.91 | $9.6K | 17,536 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award deriv | 2021-06-24 | 2021-06-28 | 4,125 | — | $0 | 4,125 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award | 2021-06-24 | 2021-06-28 | 2,145 | — | $0 | 15,695 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | A Award deriv | 2021-06-22 | 2021-06-23 | 17,500 | — | $0 | 17,500 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award deriv | 2021-06-08 | 2021-06-09 | 17,500 | — | $0 | 17,500 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award | 2021-06-08 | 2021-06-09 | 11,000 | — | $0 | 44,854 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | M Exercise deriv | 2020-07-06 | 2020-07-08 | 6,181 | — | $0 | 0 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | S Sale | 2020-07-06 | 2020-07-08 | 6,181 | $90.00 | $556.3K | 13,550 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | M Exercise | 2020-07-06 | 2020-07-08 | 6,181 | $21.00 | $129.8K | 19,731 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | M Exercise deriv | 2020-07-01 | 2020-07-06 | 5,000 | — | $0 | 6,181 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | M Exercise | 2020-07-01 | 2020-07-06 | 5,000 | $21.00 | $105.0K | 18,550 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | S Sale | 2020-07-01 | 2020-07-06 | 5,000 | $85.00 | $425.0K | 13,550 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award deriv | 2020-06-26 | 2020-06-30 | 4,250 | — | $0 | 4,250 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award | 2020-06-26 | 2020-06-30 | 2,550 | — | $0 | 13,550 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | A Award deriv | 2020-06-19 | 2020-06-22 | 12,500 | — | $0 | 12,500 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award deriv | 2020-06-16 | 2020-06-17 | 24,500 | — | $0 | 24,500 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award | 2020-06-16 | 2020-06-17 | 8,000 | — | $0 | 33,854 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | S Sale | 2020-05-18 | 2020-05-19 | 1,875 | $75.00 | $140.6K | 11,000 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | S Sale | 2020-04-22 | 2020-04-24 | 1,875 | $65.00 | $121.9K | 12,875 | SEC↗ |
| DERM Dermira, Inc. | D To issuer deriv | 2020-02-20 | 2020-02-24 | 14,224 | — | $0 | 0 | SEC↗ |
| DERM Dermira, Inc. | D To issuer deriv | 2020-02-20 | 2020-02-24 | 10,344 | — | $0 | 0 | SEC↗ |
| DERM Dermira, Inc. | D To issuer deriv | 2020-02-20 | 2020-02-24 | 10,344 | — | $0 | 0 | SEC↗ |
| DERM Dermira, Inc. | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| DERM Dermira, Inc. | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| DERM Dermira, Inc. | D To issuer deriv | 2020-02-20 | 2020-02-24 | 3,000 | — | $0 | 0 | SEC↗ |
| DERM Dermira, Inc. | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| DERM Dermira, Inc. | D To issuer | 2020-02-20 | 2020-02-24 | 5,051 | $18.75 | $94.7K | 0 | SEC↗ |
| DERM Dermira, Inc. | S Sale | 2019-12-24 | 2019-12-26 | 3,000 | $15.00 | $45.0K | 5,051 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise deriv | 2019-12-16 | 2019-12-18 | 3,500 | — | $0 | 42,092 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | S Sale | 2019-12-16 | 2019-12-18 | 3,500 | $22.50 | $78.8K | 12,536 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | M Exercise | 2019-12-16 | 2019-12-18 | 3,500 | $1.91 | $6.7K | 16,036 | SEC↗ |
| DERM Dermira, Inc. | S Sale | 2019-12-12 | 2019-12-13 | 3,000 | $12.00 | $36.0K | 8,051 | SEC↗ |
| DERM Dermira, Inc. | S Sale | 2019-09-12 | 2019-09-16 | 6,000 | $8.77 | $52.6K | 11,051 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award deriv | 2019-06-27 | 2019-07-01 | 13,000 | — | $0 | 13,000 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award | 2019-06-27 | 2019-07-01 | 4,000 | — | $0 | 25,854 | SEC↗ |
| CRNX Crinetics Pharmaceuticals, | A Award deriv | 2019-06-21 | 2019-06-25 | 12,500 | — | $0 | 12,500 | SEC↗ |
| DERM Dermira, Inc. | M Exercise deriv | 2019-06-12 | 2019-06-14 | 3,000 | — | $0 | 0 | SEC↗ |
| DERM Dermira, Inc. | M Exercise | 2019-06-12 | 2019-06-14 | 3,000 | — | $0 | 17,051 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award deriv | 2019-06-11 | 2019-06-13 | 5,000 | — | $0 | 5,000 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award | 2019-06-11 | 2019-06-13 | 3,000 | — | $0 | 14,750 | SEC↗ |
| DERM Dermira, Inc. | A Award deriv | 2019-06-04 | 2019-06-06 | 3,000 | — | $0 | 3,000 | SEC↗ |
| DERM Dermira, Inc. | A Award deriv | 2019-06-04 | 2019-06-06 | 6,000 | — | $0 | 6,000 | SEC↗ |
| MGNX MACROGENICS INC | A Award deriv | 2019-05-16 | 2019-05-20 | 10,000 | — | $0 | 10,000 | SEC↗ |
| MGNX MACROGENICS INC | M Exercise deriv | 2019-02-06 | 2019-02-08 | 6,924 | — | $0 | 0 | SEC↗ |
| MGNX MACROGENICS INC | M Exercise | 2019-02-06 | 2019-02-08 | 6,924 | $20.15 | $139.5K | 7,424 | SEC↗ |
| MGNX MACROGENICS INC | S Sale | 2019-02-06 | 2019-02-08 | 6,924 | $29.38 | $203.4K | 500 | SEC↗ |
| DERM Dermira, Inc. | S Sale | 2018-10-19 | 2018-10-19 | 4,000 | $13.75 | $55.0K | 14,051 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award deriv | 2018-06-19 | 2018-06-20 | 5,000 | — | $0 | 5,000 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award | 2018-06-19 | 2018-06-20 | 3,000 | — | $0 | 11,750 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award deriv | 2018-06-14 | 2018-06-18 | 5,000 | — | $0 | 5,000 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award | 2018-06-14 | 2018-06-18 | 1,500 | — | $0 | 21,854 | SEC↗ |
| DERM Dermira, Inc. | M Exercise deriv | 2018-06-13 | 2018-06-14 | 3,000 | — | $0 | 0 | SEC↗ |
| DERM Dermira, Inc. | M Exercise | 2018-06-13 | 2018-06-14 | 3,000 | — | $0 | 18,051 | SEC↗ |
| DERM Dermira, Inc. | A Award deriv | 2018-06-12 | 2018-06-14 | 6,000 | — | $0 | 6,000 | SEC↗ |
| DERM Dermira, Inc. | A Award deriv | 2018-06-12 | 2018-06-14 | 3,000 | — | $0 | 3,000 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | S Sale | 2018-05-30 | 2018-05-30 | 6,319 | $72.00 | $455.0K | 8,750 | SEC↗ |
| MGNX MACROGENICS INC | A Award deriv | 2018-05-17 | 2018-05-21 | 10,000 | — | $0 | 10,000 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise deriv | 2018-05-15 | 2018-05-16 | 534 | — | $0 | 0 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise | 2018-05-15 | 2018-05-16 | 534 | — | $0 | 20,354 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | S Sale | 2018-05-14 | 2018-05-16 | 12,286 | $43.57 | $535.3K | 19,820 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise deriv | 2018-02-15 | 2018-02-20 | 1,603 | — | $0 | 534 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise | 2018-02-15 | 2018-02-20 | 1,603 | — | $0 | 32,106 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise deriv | 2017-11-15 | 2017-11-17 | 1,602 | — | $0 | 2,137 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise | 2017-11-15 | 2017-11-17 | 1,602 | — | $0 | 30,503 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise deriv | 2017-08-15 | 2017-08-17 | 1,603 | — | $0 | 3,739 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise | 2017-08-15 | 2017-08-17 | 1,603 | — | $0 | 28,901 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award deriv | 2017-06-22 | 2017-06-22 | 3,750 | — | $0 | 3,750 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award | 2017-06-22 | 2017-06-22 | 1,875 | — | $0 | 15,069 | SEC↗ |
| DERM Dermira, Inc. | A Award deriv | 2017-06-13 | 2017-06-15 | 3,000 | — | $0 | 3,000 | SEC↗ |
| DERM Dermira, Inc. | A Award deriv | 2017-06-13 | 2017-06-15 | 6,000 | — | $0 | 6,000 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award deriv | 2017-06-08 | 2017-06-12 | 21,500 | — | $0 | 21,500 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award | 2017-06-08 | 2017-06-12 | 5,000 | — | $0 | 27,298 | SEC↗ |
| MGNX MACROGENICS INC | A Award deriv | 2017-05-18 | 2017-05-22 | 10,000 | — | $0 | 10,000 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise deriv | 2017-05-15 | 2017-05-17 | 1,602 | — | $0 | 5,342 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise | 2017-05-15 | 2017-05-17 | 1,602 | — | $0 | 22,298 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise deriv | 2017-02-15 | 2017-02-16 | 1,603 | — | $0 | 6,944 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise | 2017-02-15 | 2017-02-16 | 1,603 | — | $0 | 20,696 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award deriv | 2017-01-03 | 2017-01-05 | 5,500 | — | $0 | 5,500 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award | 2017-01-03 | 2017-01-05 | 2,000 | — | $0 | 19,093 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise deriv | 2016-11-15 | 2016-11-17 | 1,602 | — | $0 | 8,547 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise | 2016-11-15 | 2016-11-17 | 1,602 | — | $0 | 17,093 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise deriv | 2016-08-15 | 2016-08-17 | 1,603 | — | $0 | 10,149 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise | 2016-08-15 | 2016-08-17 | 1,603 | — | $0 | 15,491 | SEC↗ |
| DERM Dermira, Inc. | A Award deriv | 2016-06-21 | 2016-06-23 | 10,344 | — | $0 | 10,344 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award deriv | 2016-06-09 | 2016-06-14 | 3,750 | — | $0 | 3,750 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award | 2016-06-09 | 2016-06-14 | 1,875 | — | $0 | 13,194 | SEC↗ |
| MGNX MACROGENICS INC | A Award deriv | 2016-05-18 | 2016-05-20 | 8,500 | — | $0 | 8,500 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise deriv | 2016-05-16 | 2016-05-18 | 1,602 | — | $0 | 11,752 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise | 2016-05-16 | 2016-05-18 | 1,602 | — | $0 | 13,888 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise deriv | 2016-02-16 | 2016-02-18 | 1,603 | — | $0 | 13,354 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise | 2016-02-16 | 2016-02-18 | 1,603 | — | $0 | 12,286 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award deriv | 2016-01-04 | 2016-01-05 | 10,500 | — | $0 | 10,500 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise deriv | 2015-11-16 | 2015-11-18 | 1,602 | — | $0 | 14,957 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise | 2015-11-16 | 2015-11-18 | 1,602 | — | $0 | 10,683 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise deriv | 2015-08-17 | 2015-08-19 | 1,603 | — | $0 | 16,559 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise | 2015-08-17 | 2015-08-19 | 1,603 | — | $0 | 9,081 | SEC↗ |
| DERM Dermira, Inc. | M Exercise deriv | 2015-06-29 | 2015-06-30 | 9,051 | — | $0 | 14,224 | SEC↗ |
| DERM Dermira, Inc. | M Exercise | 2015-06-29 | 2015-06-30 | 9,051 | $5.51 | $49.9K | 15,051 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award deriv | 2015-06-18 | 2015-06-22 | 7,500 | — | $0 | 7,500 | SEC↗ |
| DERM Dermira, Inc. | A Award deriv | 2015-06-11 | 2015-06-15 | 10,344 | — | $0 | 10,344 | SEC↗ |
| MGNX MACROGENICS INC | A Award deriv | 2015-05-20 | 2015-05-21 | 8,500 | — | $0 | 8,500 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise deriv | 2015-05-15 | 2015-05-19 | 7,478 | — | $0 | 18,162 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | M Exercise | 2015-05-15 | 2015-05-19 | 7,478 | — | $0 | 7,478 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | M Exercise deriv | 2015-03-19 | 2015-03-23 | 6,319 | — | $0 | 11,181 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | M Exercise | 2015-03-19 | 2015-03-23 | 6,319 | $21.00 | $132.7K | 11,319 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award deriv | 2015-01-16 | 2015-01-21 | 12,500 | — | $0 | 12,500 | SEC↗ |
| DERM Dermira, Inc. | P Buy | 2014-11-25 | 2014-11-26 | 6,000 | $16.77 | $100.6K | 6,000 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award deriv | 2014-10-21 | 2014-10-23 | 25,640 | — | $0 | 25,640 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award deriv | 2014-07-10 | 2014-07-17 | 7,500 | — | $0 | 7,500 | SEC↗ |
| MGNX MACROGENICS INC | A Award deriv | 2014-06-05 | 2014-06-09 | 6,924 | — | $0 | 6,924 | SEC↗ |
| MGNX MACROGENICS INC | A Award deriv | 2014-03-05 | 2014-03-07 | 13,849 | — | $0 | 13,849 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | A Award deriv | 2014-01-30 | 2014-02-03 | 17,500 | — | $0 | 17,500 | SEC↗ |
| RARE Ultragenyx Pharmaceutical | P Buy | 2014-01-30 | 2014-02-03 | 5,000 | $21.00 | $105.0K | 5,000 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | D To issuer deriv | 2013-10-01 | 2013-10-03 | 41,596 | — | $0 | 0 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | D To issuer deriv | 2013-10-01 | 2013-10-03 | 43,044 | — | $0 | 0 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | D To issuer deriv | 2013-10-01 | 2013-10-03 | 2,856 | — | $0 | 0 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | D To issuer deriv | 2013-10-01 | 2013-10-03 | 38,981 | — | $0 | 0 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | D To issuer deriv | 2013-10-01 | 2013-10-03 | 3,019 | — | $0 | 0 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | D To issuer deriv | 2013-10-01 | 2013-10-03 | 3,904 | — | $0 | 0 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | D To issuer deriv | 2013-10-01 | 2013-10-03 | 41,450 | — | $0 | 0 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | D To issuer deriv | 2013-10-01 | 2013-10-03 | 22,600 | — | $0 | 0 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | U Tender | 2013-10-01 | 2013-10-03 | 9,153 | $125.00 | $1.14M | 31,150 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | D To issuer | 2013-10-01 | 2013-10-03 | 31,150 | $125.00 | $3.89M | 0 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2013-08-08 | 2013-08-12 | 2,492 | $128.21 | $319.5K | 40,303 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2013-07-26 | 2013-07-29 | 6,043 | $130.50 | $788.6K | 42,795 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2013-07-02 | 2013-07-05 | 308 | $132.80 | $40.9K | 48,838 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2013-07-02 | 2013-07-05 | 1,243 | $132.80 | $165.1K | 48,961 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | M Exercise deriv | 2013-05-13 | 2013-05-15 | 10,269 | — | $0 | 41,450 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2013-05-13 | 2013-05-15 | 4,269 | $97.54 | $416.4K | 56,204 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2013-05-13 | 2013-05-15 | 6,000 | $98.70 | $592.2K | 50,204 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | M Exercise | 2013-05-13 | 2013-05-15 | 10,269 | $34.48 | $354.1K | 60,473 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2013-04-15 | 2013-04-16 | 1,347 | $95.15 | $128.2K | 50,204 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2013-04-01 | 2013-04-03 | 1,167 | $86.13 | $100.5K | 54,245 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2013-04-01 | 2013-04-03 | 2,694 | $86.14 | $232.1K | 51,551 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | A Award deriv | 2013-03-28 | 2013-04-01 | 22,600 | — | $0 | 22,600 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | A Award | 2013-03-28 | 2013-04-01 | 8,000 | — | $0 | 55,412 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | M Exercise deriv | 2013-03-05 | 2013-03-05 | 2,211 | — | $0 | 51,719 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | M Exercise | 2013-03-05 | 2013-03-05 | 2,211 | $34.48 | $76.2K | 47,412 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | M Exercise deriv | 2013-02-28 | 2013-03-04 | 10,000 | — | $0 | 53,930 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | M Exercise | 2013-02-28 | 2013-03-04 | 10,000 | $34.48 | $344.8K | 60,201 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2013-02-28 | 2013-03-04 | 15,000 | $77.12 | $1.16M | 45,201 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | M Exercise deriv | 2013-01-10 | 2013-01-11 | 7,112 | — | $0 | 63,930 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | M Exercise | 2013-01-10 | 2013-01-11 | 7,112 | $34.48 | $245.2K | 60,400 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2013-01-10 | 2013-01-11 | 6,900 | $84.41 | $582.4K | 53,500 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2013-01-10 | 2013-01-11 | 3,299 | $85.83 | $283.2K | 50,201 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | M Exercise deriv | 2012-11-28 | 2012-11-30 | 966 | — | $0 | 71,042 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | M Exercise | 2012-11-28 | 2012-11-30 | 966 | $34.48 | $33.3K | 53,123 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | M Exercise deriv | 2012-08-06 | 2012-08-08 | 17,492 | — | $0 | 72,008 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2012-08-06 | 2012-08-08 | 373 | $71.93 | $26.8K | 63,407 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2012-08-06 | 2012-08-08 | 6,636 | $71.63 | $475.3K | 63,780 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2012-08-06 | 2012-08-08 | 15,000 | $71.74 | $1.08M | 70,416 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | M Exercise | 2012-08-06 | 2012-08-08 | 17,492 | $34.48 | $603.1K | 85,416 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2012-07-25 | 2012-07-27 | 5,207 | $73.97 | $385.2K | 67,924 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | D To issuer | 2012-04-02 | 2012-04-03 | 757 | $36.58 | $27.7K | 73,630 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | D To issuer | 2012-04-02 | 2012-04-03 | 820 | $36.58 | $30.0K | 72,810 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | A Award deriv | 2012-03-30 | 2012-04-03 | 45,900 | — | $0 | 45,900 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | A Award | 2012-03-30 | 2012-04-03 | 17,150 | — | $0 | 74,387 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | A Award | 2012-03-30 | 2012-04-03 | 9,000 | — | $0 | 57,237 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2012-03-02 | 2012-03-06 | 592 | $37.52 | $22.2K | 48,237 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | D To issuer deriv | 2012-02-14 | 2012-02-16 | 5,000 | — | $0 | 89,500 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | M Exercise | 2012-02-14 | 2012-02-16 | 5,000 | $34.48 | $172.4K | 48,829 | SEC↗ |
| ONXX ONYX PHARMACEUTICALS INC | S Sale | 2012-01-06 | 2012-01-10 | 1,789 | $43.46 | $77.7K | 43,829 | SEC↗ |